[go: up one dir, main page]

TW224942B - - Google Patents

Info

Publication number
TW224942B
TW224942B TW080102419A TW80102419A TW224942B TW 224942 B TW224942 B TW 224942B TW 080102419 A TW080102419 A TW 080102419A TW 80102419 A TW80102419 A TW 80102419A TW 224942 B TW224942 B TW 224942B
Authority
TW
Taiwan
Prior art keywords
cataract
medicament
manufacture
treatment
ketoprostaglandin compound
Prior art date
Application number
TW080102419A
Other languages
Chinese (zh)
Original Assignee
Adka Ueno Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adka Ueno Kk filed Critical Adka Ueno Kk
Application granted granted Critical
Publication of TW224942B publication Critical patent/TW224942B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A use of a 15-ketoprostaglandin compound for the manufacture of a medicament for treatment of cataract.
TW080102419A 1990-04-04 1991-03-28 TW224942B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP9089590 1990-04-04
JP22164690 1990-08-22
JP2931091 1991-01-29

Publications (1)

Publication Number Publication Date
TW224942B true TW224942B (en) 1994-06-11

Family

ID=27286510

Family Applications (2)

Application Number Title Priority Date Filing Date
TW081106617A TW249226B (en) 1990-04-04 1991-03-28
TW080102419A TW224942B (en) 1990-04-04 1991-03-28

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW081106617A TW249226B (en) 1990-04-04 1991-03-28

Country Status (11)

Country Link
US (2) US5212324A (en)
EP (1) EP0453127B1 (en)
KR (1) KR970005172B1 (en)
AT (1) ATE169219T1 (en)
AU (1) AU644148B2 (en)
CA (1) CA2039420C (en)
DE (1) DE69129921T2 (en)
DK (1) DK0453127T3 (en)
ES (1) ES2119762T3 (en)
GR (1) GR3027666T3 (en)
TW (2) TW249226B (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW205508B (en) * 1990-08-02 1993-05-11 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5328933A (en) * 1992-10-28 1994-07-12 Allergan, Inc. Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues
SE9303627D0 (en) * 1993-11-03 1993-11-03 Kabi Pharmacia Ab Method and means for the prevention of cataract
EP0735895B1 (en) * 1993-11-19 2006-01-18 The University Of Sydney A method for preventing or controlling cataract
SE9403160D0 (en) * 1994-09-21 1994-09-21 Pharmacia Ab Method and means for prevention and treatment of secondary cataract
DE69714698T2 (en) * 1996-06-10 2002-12-05 Sucampo Ag, Zug Endothelin antagonists
ATE227266T1 (en) * 1997-09-09 2002-11-15 Procter & Gamble AROMATIC C16-C20-SUBSTITUTED TETRAHYDRO-PROSTAGLANDINS AND THEIR USE AS PROSTAGLANDIN F AGONISTS
NZ503735A (en) * 1997-09-09 2001-05-25 Procter & Gamble Aromatic C16-20-substituted tetrahydro prostaglandin F analogues useful as FP agonists
AU739343B2 (en) * 1997-11-28 2001-10-11 Sucampo Ag Endothelin antagonist
DE60015508T2 (en) 1999-03-05 2005-04-21 Univ Durham C-16 UNAUDITED FP-SELECTIVE PROSTAGLANDIN ANALOGUE
TWI225398B (en) 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
MXPA02008967A (en) * 2000-03-16 2003-02-12 Sucampo Ag Treatment of ocular hypertension and glaucoma.
US6458836B1 (en) 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma
WO2001070233A2 (en) 2000-03-24 2001-09-27 Sucampo Ag Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
KR100874626B1 (en) * 2000-04-06 2008-12-17 수캄포 아게 Bile secretion promoting composition
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
BR0205932A (en) * 2001-08-23 2004-02-17 Sucampo Ag Method and composition for treatment of ocular hypertension and glaucoma
AU2002330747B2 (en) 2001-08-31 2007-07-19 Sucampo Ag Prostaglandin analogs as chloride channel opener
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
AU2003274735B2 (en) * 2002-10-23 2008-12-04 Sucampo Ag Prostaglandin compounds for the treatment of obesity
CA2510051C (en) 2002-12-27 2016-07-05 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
EP1641462B1 (en) * 2003-07-03 2010-11-24 Sucampo AG Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI495471B (en) * 2003-08-12 2015-08-11 R Tech Ueno Ltd Composition and method for promoting hair growth
EP1661573B1 (en) 2003-08-21 2013-09-25 Sucampo AG Ophtalmic composition comprising unoprostone ispopropyl ester and a viscosity agent
SE0303179D0 (en) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7321057B2 (en) * 2004-08-02 2008-01-22 R-Tech Ueno, Ltd. Method for manufacturing prostaglandin analogue
AR055846A1 (en) 2005-01-27 2007-09-12 Sucampo Ag COMPOSITE OF PROSTAGLANDINA AND METHOD TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS
NZ561414A (en) * 2005-03-04 2010-10-29 Sucampo Ag Method and composition for treating peripheral vascular diseases
US9241918B2 (en) 2005-03-16 2016-01-26 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
RU2468800C2 (en) * 2005-04-12 2012-12-10 Сукампо Аг Combined application of prostaglandin derivative and proton pump inhibitor for treatment of gastrointestinal diseases
WO2007086541A2 (en) 2006-01-24 2007-08-02 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
BRPI0707334B8 (en) 2006-01-24 2021-05-25 R Tech Ueno Ltd soft gelatin capsule formulation of a 15-keto-prostaglandin compound and method for stabilizing a 15-ketoprostaglandin compound
EP2789339A1 (en) 2006-03-13 2014-10-15 R-Tech Ueno, Ltd. Aqueous composition comprising 15-keto-prostaglandin
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8609729B2 (en) * 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
US8569279B2 (en) * 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
US8889735B2 (en) 2011-04-07 2014-11-18 Sucampo Ag Method for treating asthenopia
US8592483B2 (en) 2011-08-05 2013-11-26 Sucampo Ag Method for treating schizophrenia
AR092821A1 (en) 2012-04-20 2015-05-06 Sucampo Ag CONJUGATE OF GRASO-POLYMER ACID DERIVATIVE
US20150057351A1 (en) 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain
AR105029A1 (en) 2015-06-19 2017-08-30 Sucampo Ag PHARMACEUTICAL COMPOSITION THAT INCLUDES FATTY ACID DERIVATIVE

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505386A (en) * 1965-12-29 1970-04-07 Upjohn Co Compounds related to prostaglandins
US3974195A (en) * 1974-10-02 1976-08-10 The Upjohn Company 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs
EP0153858A3 (en) * 1984-02-29 1985-12-11 The Upjohn Company The therapeutic use of prostaglandins
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
ES2038289T3 (en) * 1987-05-15 1993-07-16 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo USE OF 15-CETO-PGES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO INCREASE BODY TEMPERATURE.
DE3876050T2 (en) * 1987-09-18 1993-03-25 Ueno Seiyaku Oyo Kenkyujo Kk OCULAR HYPOTENSIVAGENTS.
ES2051862T3 (en) * 1987-10-02 1994-07-01 Ueno Seiyaku Oyo Kenkyujo Kk A METHOD TO PRODUCE A DRUG THAT HAS A CATARTICAL EFFECT.
JP2597629B2 (en) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 Stabilization of 13,14-dihydro-15-ketoprostaglandins
JP2597649B2 (en) * 1988-05-11 1997-04-09 株式会社上野製薬応用研究所 Trachea / bronchodilator
AU619543B2 (en) * 1988-05-11 1992-01-30 Sucampo Ag Use of 15-ketoprostaglandin e or f compounds for uterine contraction
DE68906193T2 (en) * 1988-05-23 1993-08-05 Ueno Seiyaku Oyo Kenkyujo Kk HYPERSPHYXIA CAUSING COMPOSITION.
AU604156B2 (en) * 1988-09-14 1990-12-06 R-Tech Ueno, Ltd. Prostaglandins of the F series
EP0366279B1 (en) * 1988-10-01 1994-09-21 R-Tech Ueno Ltd. Ocular hypotensive agents
TW205508B (en) * 1990-08-02 1993-05-11 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo

Also Published As

Publication number Publication date
EP0453127B1 (en) 1998-08-05
AU7404791A (en) 1991-10-10
ES2119762T3 (en) 1998-10-16
EP0453127A3 (en) 1992-12-09
AU644148B2 (en) 1993-12-02
KR910018027A (en) 1991-11-30
TW249226B (en) 1995-06-11
US5686487A (en) 1997-11-11
US5212324A (en) 1993-05-18
DK0453127T3 (en) 1998-10-26
EP0453127A2 (en) 1991-10-23
KR970005172B1 (en) 1997-04-14
DE69129921D1 (en) 1998-09-10
CA2039420A1 (en) 1991-10-05
CA2039420C (en) 1996-12-10
DE69129921T2 (en) 1999-01-14
ATE169219T1 (en) 1998-08-15
GR3027666T3 (en) 1998-11-30

Similar Documents

Publication Publication Date Title
TW249226B (en)
DK0559413T3 (en)
GR3020902T3 (en) Use of 15-keto-prostaglandin compound for improvement of encephalic function
EP0455448A3 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
GR3019760T3 (en) Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
ES2093774T3 (en) STIMULATION OF WOUND HEALING WITH A COMPOUND 15-CETOPROSTAGLANDINA.
SG86284A1 (en) Use of (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidineacetamide for the manufacture of medicaments for the treatment of anxiety
GR3018674T3 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
EP0430551A3 (en) Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
EP0430552A3 (en) Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
GR3022217T3 (en) Treatment of cataract with prostacyclin compounds
AU639322B2 (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
GR3029726T3 (en) Use of a therapeutic compound for the treatment of bronchitis

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent